Dr. Feldman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1501 NE Medical Center Dr
Bend, OR 97701Phone+1 541-382-4900Fax+1 541-706-5273
Summary
- I have dedicated the past 20 years to pulmonary vascular disease and advanced lung disease.
I have created educational websites for pulmonary hypertension (pulmonaryhypertensionRN.com) and pulmonary fibrosis (pulmonaryfibrosisMD.com)
Education & Training
- Stanford Health Care-Sponsored Stanford UniversityFellowship, Pulmonary Disease and Critical Care Medicine, 2003 - 2004
- Brigham and Women's HospitalResidency, Internal Medicine, 1998 - 2001
- University of California San Diego School of MedicineClass of 1998
Certifications & Licensure
- AZ State Medical License 2004 - 2027
- CA State Medical License 2001 - 2026
- OR State Medical License 2021 - 2025
- MA State Medical License 2000 - 2004
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Critical Care Medicine
- American Board of Internal Medicine Pulmonary Disease
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011
Clinical Trials
- Study in Subjects With PAH and PH Secondary to IPF Using Inhaled GeNOsyl. Start of enrollment: 2011 Mar 01
- Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies Start of enrollment: 2010 Dec 01
- Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral Monotherapy Start of enrollment: 2012 Jun 26
- Join now to see all
Publications & Presentations
PubMed
- Consistent Safety and Efficacy of Sotatercept for Pulmonary Arterial Hypertension inMutation Carriers and Noncarriers: A Planned Analysis of Phase 2, Double-Blind, Pla...David Montani, Vallerie V McLaughlin, J Simon R Gibbs, Mardi Gomberg-Maitland, Marius M Hoeper
American Journal of Respiratory and Critical Care Medicine. 2025-03-04 - 1 citationsIMPAHCT: A randomized phase 2b/3 study of inhaled imatinib for pulmonary arterial hypertension.Hunter Gillies, Murali M Chakinala, Benjamin T Dake, Jeremy P Feldman, Marius M Hoeper
Pulmonary Circulation. 2024-01-01 - Erratum: Health disparities and treatment approaches in portopulmonary hypertension and idiopathic pulmonary arterial hypertension: An analysis of the Pulmonary Hypert...Hilary M DuBrock, Charles D Burger, Sonja D Bartolome, Jeremy P Feldman, David D Ivy
Pulmonary Circulation. 2022-10-01
Press Mentions
- Phase 3 INOpulse Trial Enrolls First Patient at Risk of PF-Associated PHDecember 4th, 2020
- First Patient Enrolled in Phase 3 REBUILD Trial of INOpulseDecember 4th, 2020
- New Pulmonary Hypertension Association Accreditation Program and Registry Giving New Understanding to Specialists Caring for People Living with Pulmonary HypertensionFebruary 3rd, 2017
External Links
- Pulmonary Hypertensionhttp://www.pulmonaryhypertensionRN.com
- Pulmonary Fibrosishttp://www.pulmonaryfibrosisMD.com
- Consultinghttp://JPFAdvisors.com
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: